Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A monoclonal antibody used in the treatment of chronic lymphocytic leukemia and T-cell lymphoma.

Etymologies

Sorry, no etymologies found.

Examples

  • The two companies haven ' t been able to agree on the value of Genzyme ' s efforts to turn around its Allston, Mass. plant, nor on the potential of its Campath drug, also known as alemtuzumab, which Genzyme wants to sell as a multiple-sclerosis treatment.

    Sanofi Extends Genzyme Offer

  • Sanofi to break a stalemate over the value of alemtuzumab, which is approved for blood cancer and is being tested in MS, Termeer said.

    BusinessWeek.com -- Top News

  • But the company's board has argued that Sanofi's offer does not take into account the company's recovery and its pipeline of upcoming products - including alemtuzumab, which is in late-stage testing.

    ABC News: Top Stories

  • Genzyme and Sanofi have discussed the plan as a way to break a stalemate in discussions over the value of alemtuzumab, which is approved for blood cancer and is being tested in MS.

    BusinessWeek.com -- Top News

  • Campath, approved as a therapy for blood cancer and also known as alemtuzumab, produced revenue of less than $150 million last year, according to Cambridge

    BusinessWeek.com -- Top News

  • More Genzyme coverage The market forecast for the drug -- called alemtuzumab -- was based on internal market research, consultations with patients, physicians, and health insurers, and independent analysis, according Genzyme.

    Boston.com Top Stories

  • Campath, approved as a therapy for blood cancer and also known as alemtuzumab, produced revenue of less than $150 million last year, according to Cambridge, Massachusetts-based

    Sanofi Target Genzyme’s CEO Touts Campath MS Promise - Bloomberg

  • Campath, also known as alemtuzumab, was shown to help multiple-sclerosis patients in a five-year follow-up study reported earlier this month.

    BusinessWeek.com -- Top News

  • The ongoing talks continue to focus in particular on a contingent value right, or CVR, on the U.S. biotechnology company's alemtuzumab product, a drug it hopes to market as a treatment for multiple sclerosis under the name Lemtrada.

    Sanofi Extends Genzyme Bid

  • Genzyme retained a "leading global advisory firm" to produce revenue projections for alemtuzumab for its use in multiple sclerosis.

    Genzyme Makes Case Against Sanofi

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.